Scholarlink

<p>Parkinson’s disease (PD) is a chronic, increasingly common progressive neurological disorder that ranks as the second most prevalent as the population ages. To strive to surpass to overcome this issue, chitosan nanoparticles of safinamide mesylate (CNS) were developed and tested to enhance the solubility of the drug and, as a result, its bioavailability. CNS with nanoparticle size and optimal drug entrapment was successfully prepared using the ionic gelation method. By altering the polymer ratios, five distinct batches of CNS and one batch without drug were produced. Batch CF<sub>1</sub> had particle size of 63.3&#xa0;nm, zeta potential of 30.5mv, PDI of 1.674, entrapment efficiency of 24.87% and 12.43% of SAF loading. Zeta potential was within the range of 23.6 mV for CF<sub>1</sub>, indicating stability. Entrapment efficiency and drug loading were optimum with minimum loss of drug in CF<sub>1</sub>. PXRD of CF<sub>1</sub> exists in amorphous state when scanned at 2θ and coated CNS was clearly identified by TEM images. Results of <i>Invitro</i> drug profiles studies were performed using different statistical models. CF<sub>1</sub>, followed Higuchi values are 88.31% ± 0.58%, regression value 0.9341, when compared to other batches. Accelerated stability study showed negligible changes. Prepared CNS due to its inherent nano size increased permeability of the drug and has the potential to decrease the t <sub>max</sub> and further improve bioavailability in management of Parkinson’s disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and Evaluation of Chitosan-Safinamide Mesylate Nanoparticles for the Management of Parkinson’s Disease

  • 期刊论文

  • 发表日期：

    2026年1月16日

查看全文
  • Veena Kalyani Sunkanna,
  • Vedamurthy Joshi,
  • Anoop Manjunath

摘要

Parkinson’s disease (PD) is a chronic, increasingly common progressive neurological disorder that ranks as the second most prevalent as the population ages. To strive to surpass to overcome this issue, chitosan nanoparticles of safinamide mesylate (CNS) were developed and tested to enhance the solubility of the drug and, as a result, its bioavailability. CNS with nanoparticle size and optimal drug entrapment was successfully prepared using the ionic gelation method. By altering the polymer ratios, five distinct batches of CNS and one batch without drug were produced. Batch CF1 had particle size of 63.3 nm, zeta potential of 30.5mv, PDI of 1.674, entrapment efficiency of 24.87% and 12.43% of SAF loading. Zeta potential was within the range of 23.6 mV for CF1, indicating stability. Entrapment efficiency and drug loading were optimum with minimum loss of drug in CF1. PXRD of CF1 exists in amorphous state when scanned at 2θ and coated CNS was clearly identified by TEM images. Results of Invitro drug profiles studies were performed using different statistical models. CF1, followed Higuchi values are 88.31% ± 0.58%, regression value 0.9341, when compared to other batches. Accelerated stability study showed negligible changes. Prepared CNS due to its inherent nano size increased permeability of the drug and has the potential to decrease the t max and further improve bioavailability in management of Parkinson’s disease.